Omada Health Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Membership Growth: Total members increased by 53% year-over-year to 831,000, with 79,000 net new members added in Q3.

Revenue: Q3 revenue reached $68 million, a 49% increase year-over-year.

Gross Margin: GAAP gross margin improved to 66%, with non-GAAP gross margin at 68%.

Net Loss: Reduced to $3 million from $9 million in Q3 2024.

Adjusted EBITDA: Achieved positive adjusted EBITDA of $2 million, compared to a $5 million loss in the same quarter last year.

2Strategic Updates and Business Highlights

GLP-1 Care Track: Omada announced the introduction of prescribing for anti-obesity medications within its GLP-1 Care Track, addressing market needs for managing medication alongside lifestyle support.

Innovation: Launched new AI-driven tools, including OmadaSpark and Meal Map, aimed at enhancing member engagement and support.

Research Milestones: Published its 30th peer-reviewed study, demonstrating cost savings and effectiveness of its joint and muscle health program.

Multi-Condition Platform: Continued growth in multi-condition adoption, with 75% of new customers opting for multiple programs, reflecting the appeal of an integrated approach.

3Forward Guidance and Outlook

2025 Revenue Guidance: Expected between $251.5 million and $254.5 million, up from a prior estimate of $235 million to $241 million.

Adjusted EBITDA Guidance: Forecasted to range from negative $2 million to breakeven, an improvement from previous guidance of negative $9 million to negative $5 million.

Investment Focus for 2026: Plans to invest in GLP-1 offerings and AI enhancements, aiming for sustainable growth and a long-term adjusted EBITDA target of over 20%.

4Bad News, Challenges, or Points of Concern

Cash Position: Cash and cash equivalents decreased to $199 million from $223 million in Q2 2025, attributed to debt repayment despite positive cash flow.

Market Dynamics: The competitive landscape remains challenging, particularly with the introduction of new pricing strategies for GLP-1s, which could impact margins.

Dependency on GLP-1s: While GLP-1 programs are driving growth, there is a risk of over-reliance on this segment, especially as market dynamics evolve.

5Notable Q&A Insights

GLP-1 Prescribing Details: The new prescribing initiative will be integrated within Omada’s existing care programs, with fulfillment through pharmacies. Pricing details are still being finalized.

Investment Needs: Significant investments will be required to launch the new prescribing capabilities, particularly in engineering and product development.

Demand Trends: There is strong demand for both GLP-1 Care Track and other multi-condition programs, with clients expressing interest in both reimbursement strategies and broader health solutions.

Engagement Metrics: Engagement rates remain stable, with 55% of members engaged at the end of year one, indicating effective retention strategies. Overall, Omada Health demonstrated robust growth in Q3 2025, driven by strategic innovations and a strong focus on multi-condition care, while preparing for future investments and navigating potential market challenges.